NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Crestwood Equity Partners LP (NYSE: CEQP)’s sale to Energy Transfer LP for 2.07 Energy Transfer common units for each Crestwood common unit. Upon closing, Crestwood common unitholders are expected to own approximately 6.5% of Energy Transfer’s outstanding common units. If you are a Crestwood shareholder, click here to learn more about your rights and options.
Summit Financial Group, Inc. (NASDAQ: SMMF)’s sale to Burke & Herbert Financial Services Corp. for 0.5043 shares of Burke & Herbert common stock for each share of Summit common stock. If you are a Summit shareholder, click here to learn more about your rights and options.
RPT Realty (NYSE: RPT)’s sale to Kimco Realty for 0.6049 of a newly-issued Kimco share for each RPT share. At closing, RPT shareholders are expected to own approximately 8% of the combined company. If you are a RPT shareholder, click here to learn more about your rights and options.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email email@example.com or firstname.lastname@example.org.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
- Lawsuit Oct. 20 Deadline Notice: Investors who lost over $100,000 with shares of Comerica Incorporated (NYSE: CMA) between February 2021 and May 2023 should contact the Shareholders Foundation - October 2, 2023
- A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 clinical trial of Sovateltide for the treatment of acute cerebral ischemic stroke patients - October 2, 2023
- DAV launches new Caregiver Support Program - October 2, 2023